Please wait while the formulary information is being retrieved.
HYDREA (hydroxyurea)
- squamous cell carcinoma of head and neck
- chronic myelocytic leukemia
500 mg capsule
- 20 mg/kg by oral route once daily
500 mg capsule
- 20 mg/kg by oral route once daily
Default screening record
- 80 mg/kg by oral route every 3 days
- 20 mg/kg by oral route once daily
- 15 mg/kg by oral route once daily
- 30 mg/kg by oral route once daily
- 1 capsule (500 mg) by oral route every 3 days
- 1 capsule (500 mg) by oral route once daily
- natalizumab
- Tysabri
Contraindicated
- Actimmune
- Alferon N
- Avonex
- Avonex Administration Pack
- Betaseron
- clozapine
- Clozaril
- deferiprone
- didanosine
- Extavia
- Fazaclo
- Ferriprox
- Infergen
- interferon alfa-2b
- interferon alfa-n3
- interferon alfacon-1
- interferon beta-1a
- interferon beta-1b
- interferon gamma-1b
- Intron A
- Pegasys
- Pegasys Convenience Pack
- Pegasys Proclick
- peginterferon alfa-2a
- peginterferon alfa-2b
- Pegintron
- Pegintron Redipen
- Rebif
- Rebif Rebidose
- Rebif Titration Pack
- Sylatron
- Sylatron 4-pack
- Versacloz
- Videx 2 Gram Pediatric
- Videx 4 Gram Pediatric
- Videx Ec
Severe
Moderate
- None
- Lactation
Contraindicated
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hypoplastic anemia
- Interstitial lung disease
- Neutropenic disorder
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Postirradiation erythema
HYDREA (hydroxyurea)
- squamous cell carcinoma of head and neck
- chronic myelocytic leukemia
- Infection
- Leukopenia
- Neutropenic disorder
- Anorexia
- Diarrhea
- Drowsy
- Headache disorder
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Pulmonary infiltrates
- Thrombocytopenic disorder
- Alopecia
- Constipation
- Dry skin
- Erythema
- Pruritus of skin
- Skin rash
- Stomatitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Alveolitis
- Basal cell carcinoma of skin
- Cholestasis
- CNS toxicity
- Cutaneous vasculitis
- Dermatomyositis
- Hallucinations
- Hemolytic anemia
- Hepatic failure
- Hepatitis
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Macrocytosis
- Maculopapular rash
- Malignant neoplasm of skin
- Pancreatitis
- Pulmonary fibrosis
- Radiation recall syndrome
- Secondary acute myeloid leukemia
- Seizure disorder
- Skin ulcer
- Squamous cell carcinoma of skin
- Systemic lupus erythematosus
- Tonic clonic seizure
- Tumor lysis syndrome
- Uric acid nephropathy
Less Severe
- Acute confusion
- Amenorrhea
- Azoospermia
- Chills
- Dizziness
- Dyspnea
- Dysuria
- Edema
- Fever
- Gastritis
- General weakness
- Malaise
- Nail disorders
- Oligospermia
- Skin atrophy
- Skin pigmentation enhancement
- Skin scaling
- Weight gain
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Hydroxyurea
Limited data available. Safety and efficacy not established.
Increased risk of neutropenia. Monitor growth rate.
- 1 Day – 364 Days
- Limited data available. Safety and efficacy not established.
- Increased risk of neutropenia. Monitor growth rate.
- 1 Years – 17 Years
- Limited data available. Safety and efficacy not established.
- Increased risk of neutropenia. Monitor growth rate.
Hydroxyurea
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible
Contraindicated
Hydroxyurea
Potential for serious adverse effects based on drug pharmacology
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Potential for serious adverse effects based on drug pharmacology |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Hydroxyurea
General-Increased sensitivity to effects and may require lower dose regimen. Renal-May need to reduce the dose for CrCL< 60 mL/min.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Chronic myelocytic leukemia | |
| C92.1 | Chronic myeloid leukemia, BCr/ABl-positive |
| C92.10 | Chronic myeloid leukemia, BCr/ABl-positive, not having achieved remission |
| C92.12 | Chronic myeloid leukemia, BCr/ABl-positive, in relapse |
| C92.2 | Atypical chronic myeloid leukemia, BCr/ABl-negative |
| C92.20 | Atypical chronic myeloid leukemia, BCr/ABl-negative, not having achieved remission |
| C92.22 | Atypical chronic myeloid leukemia, BCr/ABl-negative, in relapse |
| Squamous cell carcinoma of head and neck | |
| C44.02 | Squamous cell carcinoma of skin of lip |
| C44.12 | Squamous cell carcinoma of skin of eyelid, including canthus |
| C44.121 | Squamous cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.122 | Squamous cell carcinoma of skin of right eyelid, including canthus |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus |
| C44.129 | Squamous cell carcinoma of skin of left eyelid, including canthus |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus |
| C44.22 | Squamous cell carcinoma of skin of ear and external auricular canal |
| C44.221 | Squamous cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.222 | Squamous cell carcinoma of skin of right ear and external auricular canal |
| C44.229 | Squamous cell carcinoma of skin of left ear and external auricular canal |
| C44.32 | Squamous cell carcinoma of skin of other and unspecified parts of face |
| C44.320 | Squamous cell carcinoma of skin of unspecified parts of face |
| C44.321 | Squamous cell carcinoma of skin of nose |
| C44.329 | Squamous cell carcinoma of skin of other parts of face |
| C44.42 | Squamous cell carcinoma of skin of scalp and neck |
| 0-9 | A-Z |
|---|---|
| C44.02 | Squamous cell carcinoma of skin of lip |
| C44.12 | Squamous cell carcinoma of skin of eyelid, including canthus |
| C44.121 | Squamous cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.122 | Squamous cell carcinoma of skin of right eyelid, including canthus |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus |
| C44.129 | Squamous cell carcinoma of skin of left eyelid, including canthus |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus |
| C44.22 | Squamous cell carcinoma of skin of ear and external auricular canal |
| C44.221 | Squamous cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.222 | Squamous cell carcinoma of skin of right ear and external auricular canal |
| C44.229 | Squamous cell carcinoma of skin of left ear and external auricular canal |
| C44.32 | Squamous cell carcinoma of skin of other and unspecified parts of face |
| C44.320 | Squamous cell carcinoma of skin of unspecified parts of face |
| C44.321 | Squamous cell carcinoma of skin of nose |
| C44.329 | Squamous cell carcinoma of skin of other parts of face |
| C44.42 | Squamous cell carcinoma of skin of scalp and neck |
| C92.1 | Chronic myeloid leukemia, BCr/ABl-positive |
| C92.10 | Chronic myeloid leukemia, BCr/ABl-positive, not having achieved remission |
| C92.12 | Chronic myeloid leukemia, BCr/ABl-positive, in relapse |
| C92.2 | Atypical chronic myeloid leukemia, BCr/ABl-negative |
| C92.20 | Atypical chronic myeloid leukemia, BCr/ABl-negative, not having achieved remission |
| C92.22 | Atypical chronic myeloid leukemia, BCr/ABl-negative, in relapse |
Formulary Reference Tool